- authorisedHuman Pharmacology (Phase I)- Other
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001
This study is testing a new medicine, DF-006, for chronic hepatitis B. It looks at whether the medicine is safe, how the body handles it, and if it causes any side effects in healthy people and those with hepatitis B.
Romania · Bulgaria - ongoing, recruitingTherapeutic exploratory (Phase II)
HepBTer: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
This study, called HepBTer, is testing a medicine called terbinafine to see if it can help people with long-lasting hepatitis B. Researchers are looking at how safe the medicine is and if it reduces the amount of virus in the body over 10 weeks. This is an early-stage study.
Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B (HBIG for cure)
This study is looking into a new way to treat long-term (chronic) hepatitis B. It uses special antibodies, called immunoglobulins, to help the body clear the hepatitis B virus. Researchers want to see if these antibodies can make the virus disappear from the blood after 12 weeks of treatment.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II clinical trial to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B
Sweden